Edesa Biotech, Inc. — Form SCHEDULE 13D/A
Filed August 25, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
Velan Capital Investment Management LP filed an amended Schedule 13D on August 25, 2026 regarding its beneficial ownership position in Edesa Biotech, Inc. The filing provides an amendment to a prior disclosure but the specific changes to ownership percentage, share count, or dollar amounts are not visible in the header/metadata provided. Without access to the comparative details between the original and amended filing, the concrete nature and magnitude of the ownership change cannot be determined from this excerpt.
Why this rating
Schedule 13D amendments are routine regulatory filings when ownership stakes change. Without visible specifics on share counts or % changes, cannot assess materiality. Velan Capital's position relative to $14M market cap Edesa is unknown.
See more from August 25, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.